SCHEMBL4324475

SCHEMBL4324475

COc1ccc(Cl)cc1-c1ccc(C=NNC(N)=S)o1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.73
KDM4E B2RXH2 7/20 0.73
MEN1 O00255 6/20 0.73
KMT2A Q03164 6/20 0.73
ALDH1A1 P00352 6/20 0.73
LMNA P02545 6/20 0.73
NPSR1 Q6W5P4 5/20 0.73
HPGD P15428 5/20 0.73
ALOX12 P18054 2/20 0.61
PKM P14618 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
HTT P42858 1/20 0.56
MAPK1 P28482 1/20 0.55
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
SLC9A1 P19634 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4324469 1.00 MAPT (0.73) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL12417171 0.85 KDM4E (1.00) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4336412 0.84 MAPT (0.64) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4336410 0.84 MAPT (0.64) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4335641 0.82 MAPT (0.82) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4335636 0.82 MAPT (0.82) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4459532 0.81 MEN1 (0.58) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4459538 0.81 MEN1 (0.58) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4340492 0.80 KMT2A (0.69) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4340489 0.80 KMT2A (0.69) MAPTKDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885KDM4E 3010/4885MEN1 4874/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3876/4885KDM4E 2338/4885MEN1 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.